HUP0303466A3 - Method and dosage form for treating tumors by administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin - Google Patents

Method and dosage form for treating tumors by administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin

Info

Publication number
HUP0303466A3
HUP0303466A3 HU0303466A HUP0303466A HUP0303466A3 HU P0303466 A3 HUP0303466 A3 HU P0303466A3 HU 0303466 A HU0303466 A HU 0303466A HU P0303466 A HUP0303466 A HU P0303466A HU P0303466 A3 HUP0303466 A3 HU P0303466A3
Authority
HU
Hungary
Prior art keywords
tegafur
carboplatin
paclitaxel
uracil
administration
Prior art date
Application number
HU0303466A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Bristol Myers Squibb Company P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company P filed Critical Bristol Myers Squibb Company P
Publication of HUP0303466A2 publication Critical patent/HUP0303466A2/hu
Publication of HUP0303466A3 publication Critical patent/HUP0303466A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
HU0303466A 2001-03-06 2002-03-04 Method and dosage form for treating tumors by administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin HUP0303466A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27357701P 2001-03-06 2001-03-06
PCT/US2002/006262 WO2002076459A1 (en) 2001-03-06 2002-03-04 Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin

Publications (2)

Publication Number Publication Date
HUP0303466A2 HUP0303466A2 (hu) 2004-01-28
HUP0303466A3 true HUP0303466A3 (en) 2005-02-28

Family

ID=23044526

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303466A HUP0303466A3 (en) 2001-03-06 2002-03-04 Method and dosage form for treating tumors by administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin

Country Status (20)

Country Link
US (1) US6770653B2 (enExample)
EP (1) EP1368034A1 (enExample)
JP (1) JP2005506294A (enExample)
KR (1) KR20030081496A (enExample)
BR (1) BR0207443A (enExample)
CA (1) CA2439676A1 (enExample)
CZ (1) CZ20032266A3 (enExample)
EE (1) EE200300429A (enExample)
HR (1) HRP20030801A2 (enExample)
HU (1) HUP0303466A3 (enExample)
IL (1) IL157357A0 (enExample)
IS (1) IS6925A (enExample)
MX (1) MXPA03007989A (enExample)
NO (1) NO20033910L (enExample)
PL (1) PL363967A1 (enExample)
RU (1) RU2284184C2 (enExample)
SK (1) SK10602003A3 (enExample)
WO (1) WO2002076459A1 (enExample)
YU (1) YU69903A (enExample)
ZA (1) ZA200306541B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287901B6 (sk) * 2000-11-06 2012-03-02 Pharma Mar, S. A. Use of Ecteinascidin 743 for preparation of medicament for effective antitumor treatment
MXPA05009781A (es) 2003-03-14 2005-10-26 Taiho Pharmaceutical Co Ltd Potenciador de efecto antitumoral y agente antitumoral.
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
KR101287918B1 (ko) * 2004-10-26 2013-07-19 오르토 바이오테크 프로덕츠 엘.피. 엑티나시딘 ７４３과 조합된 페길화된 리포좀 독소루비신
NZ554761A (en) 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
HUE038768T2 (hu) 2005-02-18 2018-11-28 Abraxis Bioscience Llc Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2008202078B2 (en) * 2007-10-10 2012-05-31 Wellkey Holdings Limited Stability of secondary metabolite mass production through synchronized plant cell cultures
EP2201141A1 (en) * 2007-10-19 2010-06-30 Pharma Mar S.A. Prognostic molecular markers for et-743 treatment
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
KR102569221B1 (ko) * 2015-04-22 2023-08-21 신-낫 프로덕츠 엔터프라이즈 엘엘씨 공결정 조성물 및 그의 약제학적 용도
TWI787201B (zh) 2016-08-31 2022-12-21 日商富士軟片股份有限公司 抗腫瘤劑、抗腫瘤效果增強劑及抗腫瘤用套組
RU2646450C1 (ru) * 2017-05-11 2018-03-05 Владимир Михайлович Курусин Способ лечения предраковых и ранних стадий раковых заболеваний желудка
CA3089728C (en) 2018-01-29 2023-01-10 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4328229A (en) 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en) 1991-09-05 1996-07-09 Taiho Pharmaceutical Company, Ltd. Antitumor potentiator and antitumor composition
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
RU2194541C1 (ru) * 2001-07-13 2002-12-20 Научно-исследовательский институт онкологии Томского научного центра СО РАН Способ комбинированного лечения больных местнораспространенным раком желудка

Also Published As

Publication number Publication date
CZ20032266A3 (cs) 2004-02-18
US6770653B2 (en) 2004-08-03
US20020173482A1 (en) 2002-11-21
EP1368034A1 (en) 2003-12-10
IS6925A (is) 2003-08-22
RU2003129527A (ru) 2005-03-10
JP2005506294A (ja) 2005-03-03
ZA200306541B (en) 2004-11-22
IL157357A0 (en) 2004-02-19
CA2439676A1 (en) 2002-10-03
NO20033910L (no) 2003-10-23
MXPA03007989A (es) 2003-12-04
HRP20030801A2 (en) 2004-08-31
YU69903A (sh) 2006-08-17
PL363967A1 (en) 2004-11-29
KR20030081496A (ko) 2003-10-17
BR0207443A (pt) 2004-04-06
EE200300429A (et) 2003-12-15
SK10602003A3 (en) 2004-10-05
RU2284184C2 (ru) 2006-09-27
WO2002076459A1 (en) 2002-10-03
NO20033910D0 (no) 2003-09-04
HUP0303466A2 (hu) 2004-01-28

Similar Documents

Publication Publication Date Title
HUP0303466A3 (en) Method and dosage form for treating tumors by administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
IL164135A (en) 4-anilino quinazoline derivatives as antiproliferative agents, process for their preparation, pharmaceutical compositions containing such derivatives and use thereof for the preparation of medicaments for the treatment of cancer
IL162348A (en) Oxaliplatin formulations, method for stabilizing same and use thereof for preparing medicaments for treating cancer
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
HUP0402588A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them, process for producing them and their use
WO2005110994A3 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2003080582A3 (de) Fredericamycin-derivate
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
HUP0401346A3 (en) Hiv inhibiting pyrimidines derivatives, process for their preparation and pharmaceutical compositions containing them
YU91002A (sh) Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka
PL378369A1 (pl) Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji
CY1108395T1 (el) Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων
WO2005065266A8 (en) Di-substituted pyrrolotriazine compounds
WO2005105094A3 (en) Cancer treatment method
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
AU2001240001A1 (en) Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
HUP0303953A3 (en) Method for preparation of pharmaceutical composition for treating tumors by using tegafur, uracil, folinic acid, and cyclophospamide
HK1060518A (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
BR0312511A (pt) 4- (2-fluorofenil)-6-metil-2- (1-piperazinil) tieno [2,3-d] pirimidina no tratamento de distúrbio funcional dos intestinos
HK1060256A (en) Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
AU2001296746A1 (en) Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same
MXPA03008588A (es) Nuevos derivados de pirimidin-2,4,6-triona, procedimiento para su produccion y agentes farmaceuticos que contienen estos compuestos.
AU2002213119A1 (en) Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and vinorelbine and method of using the same

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished